Product Description
Ceftazidime injection is used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. (Sourced from: https://www.mayoclinic.org/drugs-supplements/ceftazidime-injection-route/side-effects/drg-20073334?p=1)
Mechanisms of Action: PBP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Spain, Thailand
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Pfizer presented P3 Hematopoietic Stem Cell Transplant|Stem Cell Transplant results on 2025-02-20 for Ceftazidime
Highest Development Phases
Phase 3: Fractures, Open
Phase 2: Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Melioidosis|Pneumonia|Pyelonephritis|Respiratory Tract Infections|Urinary Tract Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05105035 |
ARV-1801-001 | P2 |
Completed |
Melioidosis |
2023-10-10 |
50% |
2024-02-17 |
Primary Endpoints |
2023-508442-18-00 |
DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2027-12-31 |
2025-05-02 |
Treatments |
|
CTR20132859 |
CTR20132859 | P2 |
Recruiting |
Chronic Obstructive Pulmonary Disease|Urinary Tract Infections|Bronchitis, Chronic|Pneumonia|Respiratory Tract Infections|Pyelonephritis|Bronchiectasis |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20130999 |
CTR20130999 | P2 |
Active, not recruiting |
Unknown |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20131026 |
CTR20131026 | P2 |
Recruiting |
Unknown |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/04/2026 |
News Article |
Adamant Holdings Inc. acquires 100% of Green Ways S.r.l. |
|
01/22/2026 |
News Article |
DayOne Advances Finland Platform with Early-Stage Data Center Plans in Nurmijärvi |
|
11/12/2025 |
News Article |
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights |
|
11/10/2025 |
News Article |
BioVersys BV100 Phase 2b to be Conducted Via Wellcome Funded Trial Network |